Skip to content

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
PDE
Pro-Dex, Inc.PDEX
$1.52M
CONMED logo
CONMEDCNMD
$10.58M-72.0%
Vericel logo
VericelVCEL
$15.13M+299%
Anika Therapeutics logo
Anika TherapeuticsANIK
-$6.28M-112%

Other financials

Income statement

See full
Revenue$2.1B+9.3%
Gross profit$1.5B+11.1%
Operating income$373.2M+27.7%
Net income$238.1M+30.8%
EPS (diluted)$1.22+34.1%

Balance sheet

See full
Cash & equivalents$424.2M-69.4%
Total debt$7.5B+4.1%
Total equity$12.7B+2.2%
Total assets$22.7B+2.4%

Cash flow

See full
Operating cash flow$359.4M-6.1%
CapEx$36.3M-18.6%

Valuation

See full
Market cap$17.61B-6.5%
Enterprise value$24.66B-4.6%
P/E23.1×+0.3×
P/S2.1×-0.3×

Profitability

See full
Gross margin70%-1.0pp
Operating margin14%-3.0pp
Net margin9.1%-2.8pp
FCF margin17.3%-1.6pp

Returns & leverage

See full
Return on equity6.1%-1.2pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.7×

Where this comes from

Calculated from Zimmer Biomet Holdings’s reported figures.

The official record: Zimmer Biomet Holdings’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zimmer Biomet Holdings's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zimmer Biomet Holdings's free cash flow?
Zimmer Biomet Holdings (ZBH) reported free cash flow of $323.1M in Q1 2026.
How has Zimmer Biomet Holdings's free cash flow changed year-over-year?
Zimmer Biomet Holdings's free cash flow decreased by 4.5% year-over-year, from $338.2M to $323.1M.
What is the long-term trend for Zimmer Biomet Holdings's free cash flow?
Over 4 years (2021 to 2025), Zimmer Biomet Holdings's free cash flow has grown at a 2.1% compound annual growth rate (CAGR), from $1.36B to $1.47B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.